HER2 as a therapeutic target in head and neck squamous cell carcinoma.
HER2 as a therapeutic target in head and neck squamous cell carcinoma.
复制标题
DOI：
10.1158/1078-0432.ccr-14-1432
复制
发表时间：
2015-02-01
期刊：
影响因子：
--
通讯作者：
Grandis JR
中科院分区：
文献类型：
--
作者：
Pollock NI;Grandis JR
大多数头颈部鳞状细胞癌（HNSCC）患者均为晚期疾病。目前的标准治疗是手术后进行辅助放射治疗，有或没有化疗或单独放化疗。西妥昔单抗用于治疗局部晚期或复发/转移性HNSCC患者可改善总生存期和局部控制;然而，反应通常是适度的，并且治疗抵抗是常见的。正在探索各种治疗策略，以通过阻断与耐药机制有关的候选蛋白质（如HER 2）来克服西妥昔单抗耐药。几种HER 2抑制剂正在临床开发用于HNSCC，HER 2靶向治疗已被批准用于几种癌症。本文综述了HER 2的生物学特性、其在肿瘤发生中的作用以及HER 2靶向治疗HNSCC的临床研究的基本原理。
The majority of patients with head and neck squamous cell carcinoma (HNSCC) present with advanced-stage disease. Current standard of care is surgery followed by adjuvant radiation therapy with or without chemotherapy or chemoradiation alone. The addition of cetuximab for the treatment of patients with locally advanced or recurrent/metastatic HNSCC has improved overall survival and locoregional control; however, responses are often modest, and treatment resistance is common. A variety of therapeutic strategies are being explored to overcome cetuximab resistance by blocking candidate proteins implicated in resistance mechanisms such as HER2. Several HER2 inhibitors are in clinical development for HNSCC, and HER2-targeted therapy has been approved for several cancers. This review focuses on the biology of HER2, its role in cancer development, and the rationale for clinical investigation of HER2 targeting in HNSCC.